



Le moteur de votre recherche

DEPUIS 25 ans

Nanomaterials: Occupational Health and Safety Issues

Claude Ostiguy, IRSST

Tri-National Workshop on Standards for Nanotechnology


National Research Council of Canada

7 February 2007


Fullerenes

- C_{28} to $> C_{100}$
- Hollow sphere
- C_{60} is the best known

- Insoluble
- No interaction
- Very compressible
- Resumes its shape



A modified fullerene




- Made soluble by surface changes**
- Made chemically active by adducts**
- Incorporation of another product**
- Interaction with the surrounding solvent**
- **Very great variability in chemical, physical and biological behavior**

Do nanoparticles represent a health risk?


⇒ **Risk = toxicity x exposure**

Question of solubility



- **Two potential situations:**
 - Nanoparticles are **soluble** into biological fluids
 - Toxicity related to the chemical composition only
 - Toxicity normally well documented
 - **No difference between nano and microparticles deposited at the same biological site**
 - Nanoparticles are **insoluble** into biological fluids
 - ❖ ***Subject of our concern in health risk evaluation***

Pulmonary deposition of nanoparticles and ultrafine particles




Elimination from the respiratory system

- **Extrathoracic level:**
 - **Normal mechanisms**
 - *Olfactory nerve towards the brain*
- **Tracheobronchial level**
 - **Effective mucociliary elevator**
- **Alveolar level**
 - **Macrophages not very effective if < 1 micrometre**
 - **Macrophages: problems with fibres > 20 micrometres**
 - *Interstitial and alveolar epithelium translocation → movement towards the blood and lymph nodes*

Insoluble inorganic nanoparticles


- **Digestive absorption (Au):**
 - **Absorption of nanoparticles by the intestine**
 - **Passage into the blood**
 - **Distribution: brain, lungs, heart, kidneys, intestine, stomach, liver and spleen**
 - **Absorption efficiency inversely proportional to the dimension of the particles**
 - **Significant accumulation (Au) at tumor sites**



Inhalation (TiO₂)


- **Comparison of fine particles (250 nm) and agglomerated nanoparticles (20 nm) with the same final dimensions**
 - **Similar pulmonary deposition**
 - **20 nm are found in the lymph nodes**
 - **Slower pulmonary clearance → Greater pulmonary retention for nanoparticles**
 - **Greater translocation for nanoparticles**
 - **Greater pulmonary inflammation**
- ❖ *Effects correlated with the specific surface area and not the mass*
- ❖ *Effects related to surface composition and properties*

Fullerenes



- **C₆₀ alone is documented**
 - **Intraperitoneal administration**
 - **Detection in the liver, blood, spleen**
 - **Decreases enzymatic liver activity (glutathion)**
 - **Kidney disorders**
 - **Crosses the placental barrier and is distributed throughout the yolk sac and the embryo**
 - **Oral administration**
 - **98 % in feces, 2% in urine**
 - **Skin application**
 - **No effect on DNA and no cancer**
- **No pulmonary study**

Chemically modified fullerenes



■ Intravenous administration


- **Distribution in tissues: detection in the liver (73-80%), lungs (5%), kidneys (3%), spleen, heart, brain**
- **Lack of a renal clearance mechanism and nephropathy**
- **Body, thymus and heart weigh loss**
- **Spleen weigh increase**
- **Intrauterine malformations and mortality**

■ Intraperitoneal administration

- **Kidney disorders C₆₀ polyalkylsulfonates**
- **Polyhydroxylated fullerenes have shown an antioxydant potential in the lungs**
- **Hydroxylated and carboxylated functions decrease the toxicity**

■ No pulmonary study

Chemically modified fullerenes



- Depending on the functional groups, toxicity varies

From
very toxic
to
Benific

Singlewalled carbon nanotubes

■ Pulmonary toxicity

- Lung inflammation
- No effect on macrophages for very short fibers
- Bronchial pulmonary interstitial granulomas causing pneumonia and fibrosis
- Potential pulmonary toxicity related to oxidative stress – increase in inflammation biomarkers
- 10 to 25X> inflammation than silica – specific surface area

■ Cell

- Nanotube can cross the cellular membranes and be found in the nucleus - irritation

■ Skin and eyes (rats and humans)

- No allergy or irritation on skin or eyes

Multiwalled carbon nanotubes

- **Pulmonary toxicity: Intratracheal instillation**
 - **80% still in the lungs after 60 days**
 - **Phagocytosis efficiency is length dependent**
- **Cell**
 - **Nanotube can cross the cellular membranes and be found in the nucleus – irritation**
 - **Decrease in cell viability**

Insoluble organic nanoparticles

- **Interest in drug transport and targeting**
 - **Very selective therapy**
 - **Crosses the hematoencephalic barrier**
 - **Very promising tests**

- ❖ **Large variety in products but few toxicity studies on healthy organs**

Conclusion on toxicity

- **Exposure to engineered nanoparticles is likely to cause adverse health effects**
- **Surface area, surface activity (composition, Redox capacity...) and particle number should be better predictors of potential hazard than mass.**

Conclusion on toxicity (cont.)

- **Actual research results suggest that if the nanotubes are :**
 - **Longer than 20 micrometers and**
 - **In sufficient amount**

Then, we could expect the same kind of effects as biopersistent mineral fibers



- **Fibrosis**
- **Cancer**
- **Pleura modifications**
- **Mesothelioma**

Workers' exposure potential


- **During laboratory development**
- **During production:**
 - Leaks from the reactor (high T, colloids, attrition)
 - Product recovery
 - Post-production processing
 - Packaging, storage, shipping
 - Equipment maintenance
 - Spills...
- **Use and subsequent conversion:**
 - Diversity of risks related to specific applications

**Most production and conversion processes
have a potential for worker exposure**

Current knowledge on the exposure of Québec workers



NONE



Other risks and aspects of prevention

- **Nanoparticles offer a large surface area**
 - nanoscale combustible material could present a higher risk than coarser material with a similar mass concentration given its increased particle surface area and potentially unique properties due to the nanoscale
 - **Explosion risks :**
 - Large and often reactive surfaces
 - **Fire risks :**
 - Nanometric metals and great chemical reactivity
 - **Storage:**
 - Environmental conditions: humidity, temperature, chemical compatibility

Occupational Exposure Control

Rule number 1:

- Installations, processes, equipment, activities and workstations must receive particular attention

RIGHT FROM THE DESIGN STAGE

- **THREE** main categories of means of control:
 - Engineering techniques
 - Administrative means
 - Personal protective equipment

Recommended precautionary measures in the workplace

- **Unless the toxicity of the product has been established, consider very toxic and minimize the exposure**
- **Apply existing exposure control techniques**
- **When possible, implement a risk management program**
- **Implement good work practices**
- **Consider implementation of an exposure assessment program**
- **Consider implementation of a health surveillance program**

For more information

- **Two knowledge reviews are available on the IRSST web site (available in English)**

www.irsst.qc.ca

- **R-469: Health effects**
- **R-470: Risks and prevention measures**

Research team

- Claude Ostiguy, chemist, project leader, **IRSST**
- Brigitte Soucy, toxicologist, **IRSST**
- Catherine Woods, graduate student, **U. of Montréal**
- Gilles Lapointe, toxicologist, **CSST**
- Luc Ménard, industrial hygienist, **CSST**
- Yves Cloutier, aerosols engineer, **IRSST**
- Mylène Trottier, physician, **PROXIMEDUC**
- Michel Boutin, chemist, **IRSST**
- Monty Antoun, librarian, **CSST**
- Christian Normand, nanomaterials engineer, **NANOQUÉBEC**
- Charles-Anica Endo, ethicist, **NANOQUÉBEC**

Questions ?